Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LaCAR MDx Technologies develops and commercializes rapid molecular diagnostic solutions focused on newborn screening, pharmacogenetics, and detection of genetic predispositions/disorders. Their technology enables fast SNP detection without DNA extraction. The company offers complete workflows including kits, instruments, and interpretation software tailored to laboratory needs. In March 2025 they expanded their newborn screening portfolio by acquiring assets from Baebies Inc.'s newborn screening business. Products are actively marketed in Europe with local production ensuring quality control.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LaCAR MDx Technologies.